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Today, clinical evaluation of tumor heterogeneity is an emergent issue to improve clin-
ical oncology. In particular, intra-tumor heterogeneity (ITH) is closely related to cancer 
progression, resistance to therapy, and recurrences. It is interconnected with complex 
molecular mechanisms including spatial and temporal phenomena, which are often 
peculiar for every single patient. This review tries to describe all the types of ITH includ-
ing morphohistological ITH, and at the molecular level clonal ITH derived from genomic 
instability and nonclonal ITH derived from microenvironment interaction. It is important 
to consider the different types of ITH as a whole for any patient to investigate on cancer 
progression, prognosis, and treatment opportunities. From a practical point of view, 
analytical methods that are widely accessible today, or will be in the near future, are 
evaluated to investigate the complex pattern of ITH in a reproducible way for a clinical 
application.
Keywords: intra-tumor heterogeneity, morphohistological intra-tumor heterogeneity, clonal intra-tumor 
heterogeneity, functional phenotypic plasticity, stochastic plasticity, cancer spreading, genomic instability
BACKGROUND
Today, the knowledge and the clinical evaluation of tumor heterogeneity are extremely important to 
improve clinical oncology. Inter-tumor heterogeneity exceeds the boundaries of specific tumors and 
also of their molecular classifications (1, 2), which makes the clinical approach very complex. However, 
the most complex issue is intra-tumor heterogeneity (ITH) as a spatial and temporal phenomenon 
more or less distinct in every single patient. This is closely related with cancer progression, resistance 
to therapy, and recurrences. Because of ITH in primary tumors and metastases, and because of the 
wide clinical heterogeneity among patients, it is necessary to apply clinical research methods directly 
to patients’ material in today’s clinical practice to be able to better define a specific effective treatment. 
For any type of tumor, only few molecular biomarkers are being used in diagnostics at the moment, 
and a minor part of available treatment targets is applied. Hopefully, wider clinical research directly 
performed on patients will be increasingly diffused as a requirement in the near future, with the goal 
to obtain more efficient and personalized therapy protocols (3). Moreover, phase three clinical trials 
in oncology have recently encountered wide criticisms (4–6), because of the long time, the high cost, 
and not always satisfying results. They are essentially based on a patient’s randomization process, 
which is unable to cover the entire range of clinical heterogeneity. Sophisticated methods of analysis 
allow penetration in the very high complexity of cancer biology; in clinical research, those methods 
can be directly applied on the patient to cover variability in toto. Therefore, only a wide clinical 
application of research methods can lead to a correct interpretation of the clinical reality. New types 
of clinical research approaches that consider heterogeneity have recently been suggested in oncology. 
Those approaches, such as N1 trials, basket, umbrella, and platform studies, have been proposed to 
FiGURe 1 | Different types of intra-tumor heterogeneity (ITH) in an organoid 
structured multiclonal tumor: the primary clone is blue (the peripheral area is 
light blue and the central one is darker), the other clones are of different size 
and multicolor.
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overcome the limits of classical clinical trials and to shorten the 
time for a wide clinical application (7, 8).
In most papers, when it is reported about ITH, it is mostly 
dealt with clonal genetic evolution only, but ITH itself is a very 
complex matter because it is related to different sources and 
shows different patterns. Recently, also heterogeneity of drug 
distribution has been shown to be relevant in cancer treatment 
(9). There are several types of ITHs that can be observed on the 
morphological–histological and molecular level (Figure 1). All 
these should be taken into consideration when research is applied 
to clinics, because each patient needs to be considered as a whole 
also from this point of view for more effective and reproducible 
analyses.
On the morphological level, different histological heterogene-
ity patterns with different levels of differentiation are frequently 
observed in the same tumor, and it is well known that apart areas 
of the same tumor can have different patterns of gene expres-
sion also without any clonal evolution, e.g., the central part of 
the tumor compared to the external border (10). If these aspects 
of ITH are ignored, this can affect the reproducibility of clinical 
analyses and misinterpretation of the results.
On the molecular level, it is possible to distinguish at least two 
large categories of ITH, one of which is mostly clonal, transmitted 
to the daughter cells, and the other one is functional nonclonal 
(11–13). Recent literature reports have especially focused on the 
genetic clonal evolution of tumors based on DNA mutations 
and copy number alterations (CNAs). There is a lower extent of 
information on epigenetic evolution, which is also mostly clonal. 
Gene promoter methylation, general hypomethylation of tumor 
DNA, and histone methylation and deacetylation are very com-
mon in cancer and are as relevant as genetic alterations (14). The 
interaction between clonal genomic instability of cancer and the 
microenvironment leads to a nonclonal phenotypical functional 
plasticity which is related to autocrine and paracrine interac-
tions with a quite wide phenotype range. Besides phenotypical 
functional plasticity, ITH is also related to a stochastic type of 
plasticity that can affect any single cell. Even in cell lines, each cell 
is different from the others with respect to efficiency and efficacy 
of the single cell machinery with variable time and level of gene 
expression.
Methodologically, to study patients, two separate phases 
should be distinguished: one should include more or less local-
ized tumors for which surgical treatment is possible; the second 
one should involve advanced cancer and/or cancer recurrences. 
In the first case, a high level of molecular information to perform 
an effective adjuvant therapy to avoid recurrences is needed. This 
should be the main strategy to reduce cancer mortality together 
with early diagnosis procedures. The related clinical information 
is obtained from the analysis of primary tumor tissues: DNA, 
RNA, and proteins can be analyzed using extractive as well as 
in  situ methods. The molecular methods that are applied by 
maintaining the morphology, such as immunohistochemistry 
(IHC) and/or in  situ hybridization (ISH), can be specifically 
useful to study heterogeneity, preserving microenvironment 
interactions and to evaluate new types of therapy, such as immu-
notherapy (15).
As for recurrences, nowadays, an important tool, the “liquid 
biopsy,” is available. Cell-free plasma DNA (ctDNA) can be a 
useful instrument to analyze in those cases, giving important 
information for a more tailored treatment (16). New research 
methods and a closer clinical application are also appealing for 
circulating tumor cells (CTCs). This type of analysis gives further 
information especially on heterogeneity (17).
Intra-tumor heterogeneity analysis is the key for more efficient 
treatments of cancer in our patients, but only if highly reproduc-
ible clinical research is performed. We should consider that 
different aspects of ITH could be themselves one of the major 
sources of research irreproducibility, together with preclinical 
conditions of the biological materials and standardization of the 
analytical methods (11, 12).
MORPHO-HiSTOLOGiCAL iTH
Quite often, different histological patterns are present in cancer, 
which are related to different levels of differentiation and to 
metaplastic changes. It was shown in lung cancer that the different 
histological patterns of the same tumor can correlate with different 
molecular alterations (18). Even the same histotype of tumor can 
have several levels of differentiation, related to a different grade 
of atypical cells that is measured by nuclear variation and other 
characteristics. A good example of a standardized analysis of cancer 
histological heterogeneity is prostate cancer. The Gleason score ena-
bles to measure the different levels of differentiation in a tumor and 
can give a specific grade, which is closely related to prognosis (19).
There is a relationship between histological pattern and 
molecular alterations. It was shown that in lung adenocarcino-
mas, the mutant allele frequencies were higher in solid areas of 
the same tumor (18).
FiGURe 2 | Schematic representation of an organoid tumor with peripheral cells (yellow) surrounded by stroma components and phenotypically different from the 
central cells (gray). On the upper part, two metastases are schematically represented.
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The other important issue for the morphological pattern of a 
tumor is to consider distinct areas of the same tumor. Sampling 
from the border of the tumor, including the surrounding stroma 
and the sub-border in comparison with the central part of the 
tumor, can give distinctive information (Figures 1 and 2). Often, 
the border has a higher level of cellularity and higher neo-
angiogenesis than the central part, and it is well known that gene 
expression differs in central or periphery location (10). At pre-
sent, the tissue area of the tumor submitted to molecular analysis 
is hardly ever disclosed in the reports, and this could be one of 
the major issues referred to the low level of reproducibility not 
only of medicobiological research but also of diagnostics. Specific 
and standardized types of multiple sampling in larger tumors and 
microdissection in multiple sites in smaller tumors are the main 
tools that can improve reproducibility of molecular analysis in 
solid tumors, also taking ITH into account.
CLONAL iTH
For many years, it has been reported that tumor progression is 
associated with clonal evolution of the tumor cells (20). More 
recently, it has been clearly shown that this is the case in cancer 
(21). Genetic clonal evolution of cancer is related to genomic 
instability as a major feature of the carcinogenetic process. In 
recent literature, a wide description of specific genetic mecha-
nisms involved in DNA instability has been documented. There 
is evidence on increased altered DNA replication when polymer-
ases E or D are mutated (Pol-E) (22), or mismatched repair genes 
are mutated, or their promoters are methylated [microsatellite 
instability (MSI)] (23), or a chromosomal instability (CIN) with 
CNAs is present (24–26). Those mechanisms, once described in 
specific tumor types, are now reported to be differently related to 
progression and prognosis in several tumors, such as in cancer 
of endometrium, colon, pancreas, breast, lung, prostate, and 
kidney. Pol-E and MSI are connected with high ITH associated 
with a high number of DNA mutations (called ultra-mutated 
and hypermutated tumors, respectively) and with infiltration 
of tumor lymphocytes (TIL) due to the presence of a multitude 
of neo-antigens (27). Those tumors are associated with a better 
prognosis, especially for Pol-E. Neo-antigens are not only related 
to driver mutations but also related to passenger mutations, 
showing that also the latest are directly involved in cancer pro-
gression. On the other hand, a high level of CNA is also related 
to ITH, but in this case, TILs are rarer and the prognosis tends to 
be worse (27–34). Recently, it has also been shown in pancreatic 
cancer that CNAs increase in number from primary tumor to 
local lymph nodes, to distant metastases (35).
Clonal cancer evolution is related not only to DNA structural 
alterations involving protein coding genes but also to epigenetic 
mechanisms that are at the basis for altered gene expression. 
Noncoding gene alterations can be drivers in cancer progression 
(36, 37). Hypomethylation of DNA in cancer cells can trigger 
cancer-germline genes with their activation (38) and the hypo-
methylation of intra-genomic endo-parasitic DNA repeats such 
as L1 with their reactivation and retrotransposition can increase 
genomic instability (39, 40). L1 hypomethylation is present in 
NSCLC already in stage I tumors (41) and is related to worse 
survival in colon cancer stage II (42).
It is well known that tumor-suppressor genes can be meth-
ylated at the promoter level with loss of gene expression as 
one of the basic mechanisms of tumor progression, and this 
alteration can be transmitted to the next cell generations (43, 
44). Methylation patterns in lung adenocarcinomas are present 
with higher ITH as compared with somatic mutation in the same 
FiGURe 3 | High-grade ovary serus carcinoma: (A) p16 clonal type 
intra-tumor heterogeneity (ITH) and (B) Ki67 stochastic plasticity.
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tumors, suggesting to be later events in cancer progression (45). 
A CpG island methylator phenotype first described in colorectal 
cancer (46) was then reported in many different types of cancer 
as a generic disruption to epigenetic regulation (47, 48). Recently, 
it was shown that genome-wide methylation analysis can define 
pancreatic cancer subtypes (49).
Also, on the protein level, histone modification through 
methylation, deacetylation, phosphorylation, and ubiquitination 
can again silence tumor-suppressor genes or activate oncogenes 
(50–52). A new pathway was discovered in PTEN-deficient breast 
and prostate cancers with methylation of histone H3K4me3 that 
activates TNFa/NF-kB (53).
All the clonal alterations can be spatial—within the primary 
tumor (Figures 2 and 3A), sometimes involving few cells with 
difficulties for the specific detection—and temporal, with the 
acquisition of new alterations (54). They can be defined as ubiqui-
tous or truncal when, as driver mutations, they are involved in the 
carcinogenetic process from the initial phases, or shared, when 
they are shared by several different clones, and private, when they 
are specific of a single clone (21).
Clonal evolution is closely related to the applied cancer treat-
ments; ITH is connected with biological therapy resistance by 
inducing the development of minor resistant clones (55, 56). 
Cytotoxic therapy also influences ITH with the risk to select more 
aggressive clones (57, 58).
NONCLONAL iTH
One of the major sources of functional gene expression ITH is 
related to the interaction of cancer cells with the microenvironment 
(Figure 1). There is an autocrine interaction within the same clone 
cells, among different clones in a synergistic and antagonistic way 
(59–61), and a paracrine interaction with stroma components. 
All are related to clonal evolution and tumor progression (62). 
The microenvironment influences cell phenotype in any type of 
clones; the interaction can vary from area to area of the primary 
tumor, and the stroma of the tumor could be heterogeneous itself 
(63–67). All these complex interactions are known as functional 
phenotypic plasticity, which is well recognized by pathologists 
that study, e.g., epithelial–mesenchymal transition (EMT) or as 
stemness of cancer cells (68). Intermediate expression patterns 
of cells in a different functional status can be recognized with 
the use of specific biomarkers showing the continuous evolving 
functional plasticity in cancer (69). There is not only the paracrine 
influence among cancer and stroma cells but also some kind of 
interaction with the different collagen types of the stroma that can 
also have an impact on treatment outcomes (70).
Clonal genetic alterations and the microenvironment influ-
ence each other: DNA alterations are permissive for the growth 
of cancer cells, but the microenvironment may favor the devel-
opment of specific clones in comparison with others and the 
microenvironment may change in time.
In thyroid cancer, the close association of EMT and cancer 
stem-like cells (CSCs) as well as the role of exosomes and of the 
microenvironment in the metastatic phenotype were shown (71).
A crucial selection is driven by the specific microenviron-
ment induced by clinical treatments. The selection and the 
development of new prevalent clones are likely to be driven by 
clones resistant to therapy, and the new treatment associated 
with the microenvironment drives the clonal genetic evolution. 
This gives an idea of how the different clonal and nonclonal 
interactions are closely related in the clinical progression 
and in a specific way for any single patient. Recently, it has 
been suggested that tumors should be classified in a different 
way considering ITH and its development. Tumors can be 
characterized by the level of clonal evolution over time and its 
interaction with the resources available at the microenviron-
ment level (72).
A common phenomenon recognized, e.g., in immune-histo-
chemical analysis, is that positivity for a specific antigen varies 
from cell to cell in the same tumor and in the same area of the 
tumor, from negative cells to highly positive (Figure 3B). This is 
related to another type of nonclonal ITH, the so-called stochastic 
plasticity (11–13). Each cell even in a cell line in culture has dif-
ferent efficacy on the transcriptional and translational level (73), 
and chaperone proteins such as Hsp90 may modulate phenotypic 
response. As a consequence, any phenotypic expression of a nor-
mal or an altered genome is further modulated differently in every 
single cell (74). Stochastic plasticity has been recently shown to 
influence resistance to chemotherapy modulating the dynamics of 
key players in response to treatment (75). DNA damage-inducing 
agents increase the expression of p53 and at the same time of 
inhibitor of apoptosis proteins, and resistance to chemotherapy 
can be caused by stochastic fluctuations in protein levels (75).
Cancer should not be considered just as an agglomerate of 
cells, but as a functional organoid structure: the central part of 
the tumor can be hypoxic and the border well oxygenated with 
molecular metabolic exchanges between the two parts, e.g., 
lactate produced by the hypoxic cells can be metabolized on the 
mitochondrial level by the activity of lactate dehydrogenase in the 
peripheral cells with a higher level of oxygenation (Figure 2). There 
is an intra-tumor metabolic heterogeneity with different pathway 
activation, which has recently been defined in kidney cancer (76). 
Tumor hypoxia influences not only the evolution of cancer cells 
but also the development of the stromal microenvironment (77).
iTH iN MeTASTATiC SPReAD
Intra-tumor heterogeneity usually refers to intra-primary-tumor 
heterogeneity, but it is also related to inter- and intra-metastatic 
FiGURe 4 | Proposal of tumors larger than 2-cm sampling for in situ analyses: (A) multiple sampling locations and (B) organization in the inclusion block.
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heterogeneity. There are several reports in literature denying 
significant differences between primary tumors and metastases, 
but this is sometimes due to an inadequate number of analyzed 
samples as well as to the limited number of used biomarkers 
(26, 78). Clonal selection is the main mechanism underpinning 
those differences (79); therefore, it easily explains the reduced 
intra-metastatic heterogeneity reported (80). More aggressive 
and lethal clones can arise from minor subclones of the primary 
tumor even of relatively low grade (81, 82).
Monoclonal seeding of metastases has recently been dueled, 
suggesting the possibility of polyclonal seeding (80). Inter-
metastatic exchange of cancer clones that evidence the potential-
ity of metastatic sites to act as a primary tumor was also detected 
(83), and this can raise relevant considerations in favor of surgical 
treatment of the major metastases.
A recent work has shown that in most cases of colon cancer, 
the subclonal origin of the local lymph-node metastases is dif-
ferent from the distant metastases in other organs, denying the 
possibility that the latest can derive from the metastatic lymph 
nodes as often suggested (84).
The microenvironment differs between primary tumor and 
metastases influencing the phenotype of tumor cells (85). Usually, 
clinical biomarkers are only searched for in primary tumors, 
although treatments and outcomes could be better defined by 
their analysis in the metastatic tissues (86). Furthermore, by com-
paring the expression of biomarkers’ profile between primary and 
metastasis, the molecular classification of breast cancer can vary 
during cancer spreading in comparison with the primitive site. 
Clinical relevance of a specific biomarker has also been shown to 
vary if the biomarker was detected in the primary tumor or in the 
lymph-node metastasis (87).
MeTHODS TO STUDY iTH
Sampling
Fixed (mostly in formalin) and paraffin-embedded (FFPE) tis-
sues are the main resource of clinical tissue, and they are the only 
tissues available for any patient. The methods reported hereafter 
are those adapted to that type of tissues.
Most genes are not involved in clonal evolution, so it is possible 
to obtain reproducible quantitative analysis on the mRNA level 
comparing multiple samples of the same tumor taken from simi-
lar tumor areas, such as the infiltration sub-border. However, this 
is not the case, with an important difference in gene expression, 
if a specific microdissected area of the tumor is compared with 
the analysis of the entire tumor (12). To that purpose, accurate 
microdissection is required for analyses. Microdissection must 
avoid residual normal tissues that can modify the results of the 
analysis, as it is shown for several prognostic clinical signatures in 
breast cancer. The risk category changed along with the quantity 
of normal gland present in the analyzed tissue (88). An accurate 
sampling and analysis of primary tumors can give critical clinical 
information also about stroma and immune-score characteristics, 
as it has been recently shown in colon cancer (89). For analysis 
of macromolecules, microdissection is essential for comparable 
results and the microdissected area should be described in the 
report.
A preliminary type of sampling standardization has been 
proposed for solid tumors larger than 2 cm for IHC and ISH 
analyses, and it is going to be tested in the most common tumors 
for a large number of cases using the current clinical immune-
histochemical biomarkers (Figure  4). This procedure has been 
proposed for a multicentric study involving different working 
groups of the European Society of Pathology. Today, there is an 
urgent necessity to standardize sampling procedures in light of 
the hugely confusing data reported in the scientific literature 
about frequency of ITH in any type of tumor.
extractive Methods
Nowadays, nucleic acids extraction from clinical tissues can be 
a reproducible practice if it is standardized and checked with 
specific controls for FFPE tissues (90, 91). For clinical research 
activities, also samples fixed with Bouin’s solution, which has a 
higher nucleic acid level of degradation, can be used with specific 
precautions (92). To check the final progression of cancer, also 
autopsy tissues can be used in many cases (93–95).
Next-generation sequencing (NGS) sensitivity is high enough 
to detect most clonal DNA alterations. Whole-exome sequencing 
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(WES) of DNA in clinical tissues of primary tumors can detect 
several alterations present in the tumor clones that could be use-
ful for treatments. Actionable mutations could suggest the use 
of specific biological drugs for that specific tumor. Actionable 
mutations have been detected in 90% of patients by WES (mean 
4.9 per patient), a 7.5-fold, a 2.0-fold, and a 1.9-fold increase over 
the amount obtained by using the most common NGS gene pan-
els, namely CHPv2, OCP, and FoundationOne, respectively (96). 
Seventy percent of the patients have an actionable alteration with 
the availability of an approved drug, but in only 20%, the drugs 
were approved for that specific type of tumor (on-label) (97). 
Recently, it has also been shown that not only non-synonymous 
mutations are involved in drug response or resistance but also 
synonymous ones, e.g., in response to anti-EGFR therapy in colon 
cancer and head and neck squamous carcinomas (98, 99). These 
figures show the importance of clinical research directly applied 
to patients and the necessity of new types of clinical studies.
Specific attention should be given not only to a correct 
technology in NGS but also to a careful interpretation and to 
the presence of artifacts due to fixation, such as false transition 
mutations (100).
DNA and RNA single cell sequencing have already been devel-
oped, and in case of DNA, it can give important information on 
ITH (101–103), but we should be very careful in the interpreta-
tion of RNA data because the different level of expression in every 
single cell could be due to stochastic plasticity.
Several methods have been used to study epigenetics in FFPE 
tissues. For a genome-wide methylation analysis, it is possible 
to use NGS-related methods or microarrays in a representative 
tumor sample or in different microdissected tumor areas (104), 
but also other specific methods, such as methylation-specific 
multiple ligation-dependent probe amplification, have been 
used (105). To quantify all the four known DNA-methylated 
derivatives of cytosine, namely 5 methylC, 5 hydoxymethylC, 
5 formylC, and 5 carmoxylC, in FFPE tumor samples, liquid 
chromatography/mass spectrometry methods have been devel-
oped (104). Although it is less precise than LC/MS methods, also 
ELISA-based immunoquantification technology is available to 
detect the abovementioned methylated derivatives of cytosine in 
a simpler way (106).
Liquid Biopsy
The term “liquid biopsy” was originally introduced for CTCs, 
recovered from (liquid) peripheral blood (17). This method has 
rapidly improved to be shortly used also on the clinical level, the 
low number of collected cells being the major limit. Recently, cir-
culating clusters of cells instead of single CTCs have been shown 
in breast cancer patients, which are related to higher spreading, 
worse prognosis, and chemo-resistance (107). This evidence 
could explain the presence of polyclonal seeding in the cancer 
metastatic process.
Liquid biopsies do not only contain CTCs but also cell-free 
nucleic acids and exosomes. For the presence of tumor-specific 
(somatic) variations in cancers, the fraction of circulating cell-free 
plasma tumor DNA (ctDNA), together with the larger amount 
of circulating cell-free DNA from normal cells, can be used as 
specific blood-based analyses for cancer patients’ care. Thus, the 
use of a patient’s “liquid biopsy” can allow identifying residual 
micro-metastatic cancer and investigating specific mutations 
without any invasive intervention (16). “Liquid biopsy” can theo-
retically offer a real-time assessment of molecular tumor genotype 
(qualitatively) and existing tumor burden (quantitatively) and in 
this way also ITH information. The major limitation for plasma 
tumor DNA has been the low detection rate; however, new tech-
niques, such as digital PCR, have increased sensitivity (16). The 
ideal assays for liquid biopsies ctDNA would allow interrogating 
mutations in several genes at the same time, which represents a 
technical challenge because the total amount of ctDNA and its 
quality are both relatively low (56). The analysis of ctDNA can 
be helpful during the follow-up of patients to detect both trun-
cal and private mutations. However, there is the need to better 
understand the contribution of each dynamic cell population in a 
heterogeneous tumor to ctDNA (56). It is manifest that CTCs and 
ctDNA can come from different and heterogeneous metastatic 
sites; therefore, sensitivity and reproducibility in detecting tumor 
range still have to be established (108, 109). Furthermore, in the 
scenario of tumor heterogeneity it should be highlighted that these 
low invasive methods that can be repeated many times during the 
follow-up, are especially useful, because the same cancer therapy 
can drive the selection pressure that causes clonal evolution (55).
CRiSPR Barcoding in Heterogeneity
Detection of preexisting resistant subclones could be hard from a 
methodological point of view, because of their rarity. Sensitivity of 
the current methods is not enough to comprehensively consider 
cancer individual cells in heterogeneous cancer-cell populations 
(110). Recently, Guernet et  al. developed a highly sophisticated 
CRISPR-barcoding system that enables the functional investigation 
of specific mutations, in a context that closely mimics the complexity 
of cancer (111). The high-resolution tracking of single specific cancer 
cells allows identifying even rare preexisting resistant subclones that 
can be involved in acquired resistance to therapy. Using CRISPR/
Cas9 technology, the fastest ever genome engineering technology, 
and specific DNA barcodes, a strategy to recapitulate and trace the 
emergence of subpopulations of cancer cells containing a mutation 
of interest has been developed. The method has already been used to 
study mechanisms of lung cancer cell resistance to EGFR inhibitors 
and to investigate on combined drug therapies. Highly complex 
barcodes inserted in a specific genome location have been used 
to simultaneously trace the fates of many thousands of genetically 
labeled cancer cells (111). This methodology could significantly 
improve the understanding of ITH and its relationship with tumor 
progression.
Molecular Morphology
The complexity of ITH is strictly related to the biology of the 
tumor, to treatment possibilities, and to recurrence probability. 
As a consequence, we need more sophisticated, sensitive, and 
morphology-related methods that can provide information on 
different clones or different cell types at the molecular level and 
their relationship with the microenvironment. Localized complex 
phenomena, such as tumor budding, can be studied only by 
7Stanta and Bonin ITH for Clinical Use
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morphology-related methods that show close localized relation-
ship between cancer cells and stroma (65). ITH is indeed detect-
able not only among cancer cells but also at the tumor stroma 
level (112). Recently, molecular morphology has demonstrated its 
utility in predicting the efficacy of immunotherapy (15).
IHC for proteins and ISH for DNA and RNA can be success-
fully used in a reproducible way in FFPE tissues. The interplay of 
these methods in digital analysis is going to gain a more objective 
quantitative evaluation.
FISH (and other similar methods) for DNA and IHC for 
proteins have been performed for many years also at the clinical 
level, but today, we also have reproducible in  situ methods for 
mRNAs and noncoding RNAs and developing tools to detect 
most genetic, genomic, and epigenetic types of alterations. ITH 
can be studied at the in situ level for gene amplification and CIN 
with FISH (113, 114), for single nucleotide mutation (115), for 
fusion transcripts detection (116), for repetitive RNAs related 
to hypomethylation (117), and for in  situ detection of histone 
modification (118). For proteins, more sophisticated methods, 
such as matrix-assisted laser desorption/ionization imaging can 
be used (119). Most of those in situ techniques are not very widely 
diffused as methods for clinical research, and pathologists should 
improve their experience in this field.
Pre-analytical conditions of tissues are a basic prerequisite 
for reproducible results even for in situ methods. Technical CEN 
specifications are already available for extractive methods in 
FFPE tissues (DNA, RNA, and proteins) and for ctDNA from 
plasma as supported by SPIDIA4P EU project1 and developed 
by the European Committee for Standardization.2 For in  situ 
methods, ISO documents are ongoing as described in SPIDIA4P 
EU project.
CONCLUSiON
There is the necessity to consider ITH from a practical point of 
view to improve diagnosis and treatment in cancer. The major 
remarks could be the following:
 – Clinical tumor heterogeneity on the inter- or intra-tumor 
level limits the utility and the application of tumor 
1 Standardisation and improvement of generic pre-analytical tools and procedures 
for in-vitro diagnostics (SPIDIA and SPIDIA4P). Available from: http://www.
spidia.eu/about-the-projects/.
2 European Committee for Standardization (CEN). Available from https://www.
cen.eu/Pages/default.aspx.
molecular classifications based on few molecular common 
biomarkers.
 – There is an increasing necessity to apply clinical research 
directly to clinics, a research performed for the today’s patients 
with new types of studies to shorten the time for wide clinical 
application.
 – ITH in this type of research is crucial, because it is closely 
related to cancer progression, therapy resistance, and 
recurrences.
 – ITH shows different aspects in cancer, on the morphologi-
cal–histological level, and on the molecular one. Molecular 
ITH can be divided into clonal and nonclonal. The clonal one 
is related to different types of genomic instability that also 
influence aggressiveness and treatment. The nonclonal one is 
functional, microenvironment related, or stochastic, notably 
single cell efficiency related. Clonal and microenvironment 
ITHs are closely connected and influence each other.
 – All these types of ITH affect cancer progression and treat-
ment efficacy and should be considered as a whole for any 
patient.
 – At least two types of ITH methodological approaches should 
be considered: in surgically treated tumors, a careful analysis 
of tissues should drive the adjuvant therapy, and in recurrent 
cancer, the follow-up should consider the inclusion of blood 
analysis of ctDNA and, in a near future, also CTCs.
 – Actionable mutations and resistance alterations should also 
be detected in minor clones to establish a better and tailored 
treatment.
 – For tissues, multiple microdissection of tissues should be 
performed, and for larger tumors, a standardized multiple 
sampling procedure should be adopted to increase analysis 
reproducibility.
 – Pathologists should improve their experience in in situ meth-
ods to better study clonal and microenvironment interactions.
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